CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

New AHA/ACC/HRS Guidance on Sudden Cardiac Death Prevention Know Diabetes by Heart: A Partnership to Improve Cardiovascular Outcomes in Type 2 Diabetes Mellitus Left Main Stenting: What We Have Learnt So Far? Lack of Association Between Heart Failure and Incident Cancer Uptake of Drug-Eluting Bioresorbable Vascular Scaffolds in Clinical Practice : An NCDR Registry to Practice Project Cardiac Troponin Composition Characterization after Non ST-Elevation Myocardial Infarction: Relation with Culprit Artery, Ischemic Time Window, and Severity of Injury Comparison in prevalence, predictors, and clinical outcome of VSR versus FWR after acute myocardial infarction: The prospective, multicenter registry MOODY trial-heart rupture analysis Myocardial Inflammation Predicts Remodeling and Neuroinflammation After Myocardial Infarction Impact of Oxidative Stress on the Heart and Vasculature: Part 2 of a 3-Part Series 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Review Article2017 Nov 10 [Epub ahead of print]

JOURNAL:Cardiovasc Revasc Med. Article Link

Left-main restenosis in the DES era-a call for action

di Palma G, Cortese B Keywords: In-stent restenosis; Sirolimus-coated balloon; Unprotected left main

ABSTRACT

Percutaneous treatment of the unprotected left main trunk (ULM), defined as a vessel without patent bypass graft either to the left circumflex (LCX) or left anterior descending (LAD) artery, has gained a precise role thanks to recent scientific evidence. Although new generation drug-eluting stents have already proven to be safer, there is still a consistent risk of restenosis and late adverse events. The optimal management of a ULM restenosis is still debated. Here we aim at presenting a review of the available data in literature and show our choice for treating it.